Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
VEGF trap
Ziv-aflibercept
Zaltrap · Afli
A soluble VEGF trap that, like bevacizumab, hits the glomerulus with hypertension, proteinuria and TMA.
ModerateVEGF trap (decoy receptor) · approved 2012
Metastatic colorectal cancer (with FOLFIRI)
Signature kidney injury
Hypertension
Hypertension and proteinuria are common class effects; in the registrational VELOUR trial, grade 3-4 hypertension and proteinuria were notably more frequent with aflibercept plus FOLFIRI than with FOLFIRI alone. Nephrotic-range proteinuria and renal thrombotic microangiopathy are documented, including with the ophthalmic formulation, indicating a direct VEGF-trap mechanism.
Source: Van Cutsem et al., VELOUR (J Clin Oncol 2012 / Target Oncol 2016); Kikuchi et al., BMC Nephrol 2022
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
GlomerulusFiltration barrier (podocytes + endothelium)
Vasculature / EndotheliumGlomerular & peritubular capillaries
Hypertension
On-target loss of endothelial nitric oxide from VEGF-pathway blockade — so consistent it marks drug activity.
Mechanism of kidney injury
Sequestration of circulating VEGF-A (and PlGF) removes the endothelial survival and permeability signaling that maintains fenestrated glomerular endothelium, causing endothelial injury, loss of fenestrae, podocyte stress and proteinuria, reduced nitric-oxide-dependent vasodilation (hypertension), and renal-limited thrombotic microangiopathy. Because aflibercept binds the ligand itself (like bevacizumab), it produces a TMA-predominant lesion rather than the MCD/FSGS pattern more typical of receptor-blocking TKIs.
Clinical presentation
Hypertension with new proteinuria, sometimes nephrotic-range with edema; biopsy shows TMA (glomerular endotheliosis, capillary-wall double contours, mesangiolysis, intracapillary foam cells) and foot-process effacement.
Onset
Within weeks to a few months of therapy.
Reversibility
Reversible
Anticancer mechanism
Recombinant fusion protein combining the second Ig domain of VEGFR1 and the third Ig domain of VEGFR2 fused to the Fc of human IgG1, acting as a high-affinity soluble decoy that binds and sequesters VEGF-A, VEGF-B and placental growth factor (PlGF), blocking their interaction with native receptors and inhibiting angiogenesis. Used with FOLFIRI in metastatic colorectal cancer previously treated with an oxaliplatin regimen.
Management
Antihypertensive therapy (ACE inhibitor/ARB favored); per label, suspend for urine protein >=2 g/24 h and resume at a lower dose when <2 g/24 h, and discontinue for nephrotic syndrome or any TMA. Renal abnormalities typically improve after drug discontinuation.
Risk factors
- Pre-existing hypertension
- Diabetes or baseline proteinuria/CKD
Prevention
- Baseline and periodic blood pressure and urine protein (UPCR) monitoring
- Aggressive blood pressure control before and during therapy
Note · Direct VEGF-A sequestration (like bevacizumab) predisposes to renal-limited TMA more than to glomerulopathy alone. The 'ziv-' prefix distinguishes the oncology formulation from intravitreal aflibercept, but the renal mechanism is identical.
Clinical depth
Renal dose adjustment
No pharmacokinetic renal dose adjustment for a fusion-protein decoy; dose modification is driven by proteinuria thresholds and hypertension grade. Renal impairment does not alter clearance of the Fc-fusion molecule.
Dialyzability & ESKD dosing
Not dialyzable — a ~115 kDa Fc-fusion protein is not removed by hemodialysis or peritoneal dialysis; no dose change for dialysis patients.
Differential diagnosis
Ligand-trap (aflibercept/bevacizumab) renal injury skews toward TMA/endotheliosis on biopsy, contrasting with the MCD/FSGS pattern of VEGFR-TKIs; distinguish also from prerenal AKI and from chemotherapy (oxaliplatin/5-FU) effects within the FOLFIRI backbone.
Monitoring
- Blood pressure every 2 weeks or with each cycle
- Urine dipstick/UPCR before each dose; 24-h collection if >=2+
- Serum creatinine; CBC/LDH/haptoglobin and smear if TMA suspected
Key trials & series
- VELOUR phase III trial of aflibercept + FOLFIRI in second-line metastatic colorectal cancer (carrying the hypertension/proteinuria signal)
- Kikuchi et al. biopsy-proven aflibercept-associated renal TMA case (BMC Nephrol 2022)
Clinical pearls
- As a VEGF ligand trap, aflibercept causes a TMA-type glomerular lesion, mirroring bevacizumab and the Eremina knockout model.
- The label gives explicit proteinuria thresholds (suspend at >=2 g/24 h; stop for nephrotic syndrome/TMA).
- Even intravitreal aflibercept has caused renal TMA, underscoring how little systemic VEGF blockade the glomerulus tolerates.
Where it strikes
Nephron segments
Glomerulus
Filtration barrier (podocytes + endothelium)
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
HypertensionGlomerular Injury / ProteinuriaThrombotic Microangiopathy
Beyond the kidney
Class-level context for the major non-renal toxicities of vegf traps.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- LV dysfunction; QT (some TKIs)
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea, perforation/fistula
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Hand-foot skin reaction
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkVEGF inhibition and renal thrombotic microangiopathy.Eremina V et al. · N Engl J Med 2008 · PMID 18337603Landmark mechanistic proof that VEGF ligand sequestration causes glomerular TMA.PMIDAflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study.Van Cutsem E et al. · Target Oncol 2016 · PMID 26706237Registrational VELOUR program, the source of the aflibercept hypertension/proteinuria safety signal.PMIDRenal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema.Kikuchi Y et al. · BMC Nephrol 2022 · PMID 36309669Biopsy-proven aflibercept-associated renal TMA and nephrotic proteinuria, reversible on withdrawal.PMIDTherapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.Estrada CC et al. · J Am Soc Nephrol 2019 · PMID 30642877Mechanistic review: VEGF traps are specifically associated with renal-limited TMA.PMIDThe Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread".Sanidas E et al. · Am J Hypertens 2018 · PMID 29788148Reviews antiangiogenic hypertension pathophysiology and management.PMID[Nephrotoxicity of anti-angiogenesis drugs].Grechukhina KS et al. · Ter Arkh 2020 · PMID 33346501Review of antiangiogenic-drug nephrotoxicity and thrombotic microangiopathy.
Related agents
Other agents sharing the same signature kidney injury.